Molecular modelling of mammalian CYP2B isoforms and their interaction with substrates, inhibitors and redox partners

Xenobiotica

Volumn 27, Issue 5, 1997, Pages 443-478

  Lewis, D F V ^a   Lake, B G ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; BARBITAL; BENZPHETAMINE; CHLORAMPHENICOL; CHLORPHENOTANE; COCAINE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 ISOENZYME; ENZYME INHIBITOR; FEPRAZONE; HEXOBARBITAL; METYRAPONE; NICOTINE; PHENOBARBITAL; PHENYLBUTAZONE; PROADIFEN; SECOBARBITAL; TAMOXIFEN; TESTOSTERONE;

ARTICLE; ENZYME SUBSTRATE; HUMAN; MOLECULAR MODEL; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RABBIT; RAT;

AMINO ACID SEQUENCE; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; HEXOBARBITAL; HUMANS; ISOENZYMES; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OXIDATION-REDUCTION; PHENOBARBITAL; PHENYLBUTAZONE; PRENAZONE; RABBITS; RATS; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TEMPLATES, GENETIC;

EID: 0030963222     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240433     Document Type: Article

References (102)

1. ALEXANDER, D. M., MATHEW, G. E. A. and WILSON, B. J., 1985, Metabolism of phenylbutazone in rats. Xenobiotica, 15, 123-128.
2. AOYAMA, T., KORZEKWA, K., NAGATA, K., ADESNIK, M., REISS, A., LAPENSON, D. P., GILLETTE, J., GELBOIN, H. V., WAXMAN, D. J. and GONZALEZ, F. J., 1989, Sequence requirements for cytochrome P-450IIB1 catalytic activity. Journal of Biological Chemistry, 264, 21327-21333.
3. BERNHARDT, R., 1993, Chemical probes of cytochrome P450 structure. In Cytochrome P450, edited by J. B. Schenkman and H. Griem (Berlin: Springer), pp. 547-560.
4. BERNHARDT, R., 1995, Cytochrome P450: structure, function, and generation of reactive oxygen species. Reviews of Physiology, Biochemistry and Pharmacology, 127, 137-221.
5. BERNHARDT, R., KRAFT, R., OTTO, A. and RUCKPAUL, K. 1988, Electrostatic interactions between cytochrome P450 LM2 and NADPH-cytochrome P450 reductase. Biomedica et Biophysica Acta, 47, 581-592.
6. BERNHARDT, R., KRAFT, R. and RUCKPAUL, K., 1989a, Molecular mechanism of P-450/reductase interaction. In Cytochrome P-450: Biochemistry and Biophysics, edited by I. Schuster (London: Taylor & Francis), pp. 320-323.
7. BERNHARDT, R., MAKOWER, A., JÄNIG, G.-R. and RUCKPAUL, K., 1984, Selective chemical modification of a functionally linked lysine in cytochrome P-450 LM2. Biochimica et Biophysica Acta, 785, 186-190.
8. BERNHARDT, R., STIEL, H. and RUCKPAUL, K., 1989b, Distance between lysine 384 and haem of cytochrome P-450 LM2 (P-450IIB4) studied by fluorescence energy transfer measurements. Biochemical and Biophysical Research Communications, 163, 1282-1289.
9. BERRY, D. J., WEDLEY, M., GRAHAME, R., GOULDING, R., GAETANI, M. and PARKE, D. V., 1993, Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance. Xenobiotica, 23, 1231-1240.
10. BLANCK, J., REIN, H., SOMMER, M., RISTAU, O., SMETTAN, G. and RUCKPAUL, K., 1983, Correlations between spin equilibrium shift, reduction rate, and N-demethylation activity in liver microsomal cytochrome P-450 and a series of benzphetamine analogues as substrates, as Biochemical Pharmacology, 32, 1683-1688.
11. BORIES, G. F. and CRAVEDI, J.-P., 1994, Metabolism of chloramphenicol: a story of nearly 50 years. Drug Metabolism Reviews, 26, 767-783.
12. BUENING, M. K. and FRANKLIN, M. R., 1976, SKF-525A inhibition, induction, and 452 nm complex formation. Drug Metabolism and Disposition, 4, 244-255.
13. BURKE, M. D., THOMPSON, S., ELCOMBE, C. R., HALPERT, J., HAAPARANTA, T. and MAYER, R. T., 1985, Ethoxy-, pentoxy- and benzyloxy phenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochemical Pharmacology, 34, 3337-3345.
14. CLARK, M., CRAMER, R. D. and VAN OPDENBOSCH, N., 1989, Validation of the general purpose Tripos 5·2 force field. Journal of Computational Chemistry, 10, 982-1012.
15. eryF involved in erythromycin biosynthesis. Structural Biology, 2, 144-155.
16. DE LEMOS-CHIARANDINI, C., FREY, A. B., SABATINI, D. D. and KREIBICH, G., 1987, Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4 using site-specific antibodies. Journal of Cell Biology, 104, 209-219.
17. DEGTYARENKO, K. N. and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Letters, 332, 1-8.
18. DEHAL, S. S. and KUPFER, D., 1994, Metabolism of the proestrogenic pesticide methoxychlor by hepatic P450 monooxygenases in rats and humans. Drug Metabolism and Disposition, 22, 937-946.
19. ELDIRDIRI, N., 1992, Uptake and metabolic effects of some halogenoalkanes. PhD thesis, University of Surrey.
20. 5. Archives of Biochemistry and Biophysics, 271, 424-432.
21. 14C-DDMU in rats and Japanese quail. Xenobiotica, 17, 525-538.
22. GIBSON, G. G. and TAMBURINI, P. P., 1984, Cytochrome P-450 spin state: inorganic biochemistry of haem iron ligation and functional significance. Xenobiotica, 14, 27-47.
23. GONZALEZ, F. J. and GELBOIN, H. V., 1994, Roles of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metabolism Reviews, 26, 165-183.
24. GOTOH, O., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83-90.
25. GRAHAM-LORENCE, S. and PETERSON, J. A., 1996, P450s: structural similarities and functional differences. FASEB Journal, 10, 206-214.
26. HALPERT, J. R., 1995, Structural basis of selective cytochrome P450 inhibition. Annual Reviews of Pharmacology and Toxicology, 25, 29-53.
27. HALPERT, J. R., GUENGERICH, F. P., BEND, J. R. and CORREIA, M. A. 1994, Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology, 125, 163-175.
28. HALPERT, J. R. and HE, Y., 1993, Engineering of cytochrome P450 2B1 specificity. Journal of Biological Chemistry, 268, 4453-4457.
29. HALPERT, J. R., HE, Y., SZKLARZ, G. D., HE, Y., HASLER, J. A., BURNETT, V. L., HARLOW, G. R., KLETOTKA, P. A. and JOHN, G. H., 1995, Alteration of cytochrome P450 substrate specificity by site-directed mutagenesis: application to drug metabolism studies. In Proceedings of the 4th ISSX Meeting, Seattle, Washington, 27-31 August 1995, p. 41.
30. HALPERT, J. R., MILLER, N. E. and GORSKY, L. D., 1985, On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. Journal of Biological Chemistry, 260, 8397-8403.
31. HAMMOND, D. K., BJERCKE, R. J., LANGONE, J. J. and STROBEL, H. W., 1991, Metabolism of nicotine by rat liver cytochromes P-450. Drug Metabolism and Disposition, 19, 804-808.
32. HASEMANN, C. A., KURUMBAIL, R. G., BODDUPALLI, S. S., PETERSON, J. A. and DEISENHOFER, J., 1995, Structure and function of cytochromes P450: a comparative analysis of three crystal structures. Structure, 3, 41-62.
33. HASLER, J. A., HARLOW, G. R., SZKLARZ, G. F., JOHN, G. H., KEDZIE, K. M., BURNETT, V. L., HE, Y.-A., KAMINSKY, L. S. and HALPERT, J. R., 1994, Site-directed mutagenesis of putative substrate recognition sites in cyothcrome P450 2B11: importance of amino acid residues 114, 290 and 363 for substrate specificity. Molecular Pharmacology, 46, 338-345.
34. HE, Y., BALFOUR, C. A., KEDZIE, K. M. and HALPERT, J. R., 1992, Role of residue 478 as a determinant of the substrate specificity of cytochrome P450 2B1. Biochemistry, 31, 9220-9226.
35. HE, Y., LUO, Z., KLEKOTKA, P. A., BURNETT, V. L. and HALPERT, J. R., 1994, Structural determinants of cytochrome P450 2B1 specificity: evidence for five substrate recognition sites. Biochemistry, 33, 4419-4424.
36. IBEANU, G. C., GHANAYEM, B. I., LINKO, P., LI, L., PEDERSEN, L. G. and GOLDSTEIN, J. A., 1996, Identification of residues 99, 220 and 221 of human cytochrome P4502C19 as key determinants of omeprazole hydroxylase activity. Journal of Biological Chemistry, 271, 12496-12501.
37. INOUYE, K. and COON, M. J., 1985, Properties of the tryptophan residue in rabbit liver microsomal cytochrome P-450 isozyme 2 as determined by fluorescence. Biochemical and Biophysical Research Communications, 128, 676-682.
38. JANSSON, I., 1993, Post translational modification of cytochrome P450. In Cytochrome P450, edited by J. B. Schenkman and H. Grien (Berlin: Springer), pp. 561-580.
39. JANSSON, I., CURTI, M., EPSTEIN, P. M., PETERSON, J. A. and SCHENKMAN, J. B., 1990, Relationship between phosphorylation and cytochrome P450 destruction. Archives of Biochemistry and Biophysics, 283, 285-292.
40. JEFCOATE, C. R. E., GAYLOR, J. L. and CALABRESE, R. L. 1969, Ligand interactions with cytochrome P-450. I. Binding of primary amines. Biochemistry, 8, 3455-3463.
41. JOHNSON, E. F., 1992, Mapping determinants of the substrate selectivities of P450 enzymes by site-directed mutagenesis. Trends in Pharmaceutical Sciences, 13, 122-126.
42. KAMINSKY, L. S., KENNEDY, M. W., ADAMS, S. M. and GUENGERICH, F. P., 1981, Metabolism of dichlorobiphenyls by highly purified isozymes of rat liver cytochrome P-450. Biochemistry, 20, 7379-7384.
43. KEDZIE, K. M., BALFOUR, C. A., ESCOBAR, G. Y., GRIMM, S. W., HE, Y., PEPPERL, D. J. REGAN, J. W., STEVENS, J. C. and HALPERT, J. R., 1991, Molecular basis for a functionally unique cytochrome P450IIB1 variant. Journal of Biological Chemistry, 266, 22515-22521.
44. KENNEDY, M. W., CARPENTIER, N. K., DYMERSKI, P. P. and KAMINSKY, L. S., 1981, Metabolism of dichlorobiphenyls by hepatic microsomal cytochrome P-450. Biochemical Pharmacology, 30, 577-588.
45. KING, C. M., 1995, Tamoxifen and the induction of cancer. Carcinogenesis, 16, 1449-1454.
46. KOLESANOVA, E. F., KOZIN, S. A., LEMESHKO, A. O. and ARCHAKOV, A. I., 1994, Epitope mapping of cytochrome P450 2B4 by peptide scanning. Biochemistry and Molecular Biology International, 32, 465-473.
47. LAKE, B. G. and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (Boca Raton: CRC Press) pp. 269-295.
48. LEVIN, S. S., VARS, H. M., SCHLEYER, H. and COOPER, D. Y., 1986, The metabolism and excretion of enzyme-inducing doses of phenobarbital by rats with bile fistulas. Xenobiotica, 16, 213-224.
49. bm3). Xenobiotica, 25, 333-366.
50. LEWIS, D. F. V., 1996a, Cytochromes P450: Structure, Function and Mechanism. (London: Taylor and Francis).
51. LEWIS, D. F. V., 1996b, Quantitative structure-activity relationships in substrates, inducers and inhibitors of cytochrome P4501 (CYP1). Drug Metabolism Reviews (in press).
52. LEWIS, D. F. V., 1996c, Molecular orbital calculations on primary aliphatic amines: Correlations with binding to cytochrome P4502B4 (CYP2B4) and quantitative structure-activity relationships. Biochemical Pharmacology (submitted).
53. LEWIS, D. F. V., EDDERSHAW, P. J., GODLFARB, P. S. and TARBIT, M. H., 1996, Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica, 26, 1067-1086.
54. LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1987, Structural requirements for substrates of cytochromes P-450 and P-448. Chemico-Biological Interactions, 64, 39-60.
55. LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1995b, A quantitative structure-activity relationship study on a series of 10 para-substituted toluenes binding to cytochrome P4502B4 (CYP2B4), and their hydroxylation rates. Biochemical Pharmacology, 50, 619-625.
56. LEWIS, D. F. V. and LAKE, B. G., 1995, Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity. Xenobiotica, 25, 585-598.
57. LEWIS, D. F. V. and LAKE, B. G., 1996, Molecular modelling of the CYP1A subfamily members based on an alignment with CYP102: rationalization of CYP1A substrate specificity in terms of active site amino acid residues. Xenobiotica, 26, 723-753.
58. LEWIS, D. F. V., LAKE, B. G. and PARKE, D. V., 1995a, Molecular orbital-generated QSARs in an homologous series of alkoxyresorufins and studies of their interactive docking with cytochromes P450. Xenobiotica, 25, 1355-1369.
59. LEWIS, D. F. V. and MOEREELS, H., 1992, The sequence homologies of cytochromes P-450 and active site geometries. Journal of Computer-Aided Molecular Design, 6, 235-252.
60. LEWIS, D. F. V., TAMBURINI, P. P. and GIBSON, G. G., 1986, The interaction of a homologous series of hydrocarbons with hepatic cytochrome P-450. Molecular orbital-derived electronic and structural parameters influencing the haemoprotein spin-state. Chemico-Biological Interactions, 58, 289-299.
61. LUNETTA, J. M., SUGIYAMA, K. and CORREIA, M. A., 1989, Secobarbital-mediated inactivation of rat liver cytochrome P-450b: a mechanistic reappraisal. Molecular Pharmacology, 35, 10-17.
62. MANI, C., GELBOIN, H. V., PARK, S. S., PEARCE, R., PARKINSON, A. and KUPFER, D., 1993, Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. Drug Metabolism and Disposition, 21, 645-656.
63. MILLER, J. P. AND HALPERT, J. R., 1986, Analogues of chloramphenicol as mechanism-based inactivators of rat liver cytochrome P-450: modifications of the propanediol side chain, the p-nitro group, and the dichloromethyl moiety. Molecular Pharmacology, 29, 391-398.
64. MILLER, J. P., HERBETTE, L. G. and WHITE, R. E., 1996, X-ray diffraction analysis of cytochrome P450 2B4 reconstituted into liposomes. Biochemistry, 35, 1466-1474.
65. MURRAY, M., 1992, P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clinical Pharmacokinetics, 23, 132-146.
66. MURRAY, M. and REIDY, G. F., 1990, Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacological Reviews, 42, 85-101.
67. NAU, H., SPIELMAN, LO TURCO MORLET, C. M., WINCKLER, K., RIEDEL, L. and OBE, G., 1982, Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives. Mutation Research, 95, 105-118.
68. NEDELCHEVA, V. and GUT, I., 1994, P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica, 24, 1151-1175.
69. NEGISHI, M., IWASAKI, M., JUVONEN, R. O., SUEYOSHI, T., DARDEN, T. A. and PEDERSEN, L. G., 1996, Structural flexibility and functional versatility of cytochrome P450 and rapid evolution. Mutation Research, 350, 43-50.
70. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
71. ORTIZ DE MONTELLANO, P. R., 1987, Control of the catalytic activity of prosthetic haem by the structure of hemoproteins. Accounts of Chemical Research, 20, 289-294.
72. ORTIZ DE MONTELLANO, P. R., CHAN, W. K., TUCK, S. F., KAIKUS, R. M., BASS, N. M. and PETERSON, J. A., 1992, Mechanism-based probes of the topology and function of fatty acid hydroxylases. FASEB Journal, 6, 695-699.
73. ORTIZ DE MONTELLANO, P. R. and CORREIA, M. A., 1995, Inhibition of cytochrome P450 enzymes. In Cytochrome P450, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 305-364.
74. 1′(5′) iminium species. Journal of Medicinal Chemistry, 30, 249-254.
75. PETZOLD, D. R., REIN, H., SCHWARZ, D., SOMMER, M. and RUCKPAUL, K., 1985, Relation between the structure of benzphetamine analogues and their binding properties to cytochrome P-450 LM2. Biochimica et Biophysica Acta, 829, 253-261.
76. POET, T. S., BRENDEL, K. and HALPERT, J. R., 1994, Inactivation of cytochromes P450 2B protects against cocaine-mediated toxicity in rat liver slices. Toxicology and Applied Pharmacology, 126, 26-32.
77. POON, G. K., CHUI, Y. C., MCCAGUE, R., LONNING, P. E., FENG, R., ROWLANDS, M. G. and JARMAN, M., 1993, Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism and Disposition, 21, 1119-1124.
78. BM-3, a prototype for microsomal P450s. Science, 261, 731-736.
79. ROFFEY, S. J., 1993, Structure-activity relationships in the metabolism of a series of tertiary amines by cytochrome P450. PhD thesis, University of Surrey.
80. ROSSI, M., MARKOVITZ, S. and CALLAHAN, T., 1987, Defining the active site of cytochrome P-450: the crystal and molecular structure of an inhibitor, SKF-525A. Carcinogenesis, 8, 881-887.
81. cam and BM-3 as templates: implications for the substrate binding pocket. Protein Engineering, 7, 1345-1351.
82. RUZICKA, J. A. and RUENITZ, P. C., 1992, Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metabolism and Disposition, 20, 770-772.
83. RYAN, D. E. and LEVIN, W., 1990, Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacology and Therapeutics, 45, 153-239.
84. SCHENKMAN, J. B., SLIGAR, S. G. and CINTI, D. L., 1981, Substrate interaction with cytochrome P-450. Pharmacology and Therapeutics, 12, 43-71.
85. SCHWARZE, W., BLANCK, J., RISTAU, O., JANIG, G. R., POMMERENING, K., REIN, H. and RUCKPAUL, K., 1985, Spin state control of cytochrome P-450 reduction and catalytic activity in a reconstituted P-450 LM2 system as induced by a series of benzphetamine analogus. Chemico-Biological Interactions, 54, 127-141.
86. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians. Journal of Pharmacology and Therapeutics, 270, 414-423.
87. SOUCEK, P. and GUT, I., 1992, Cytochromes P-450 in rats: structures, functions, properties and relevant human forms. Xenobiotica, 22, 83-103.
88. SPATZENEGGER, M. and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism. Drug Metabolism Reviews, 27, 397-417.
89. SWANSON, B. A., DUTTON, D. R., LUNETTE, J. M., YANG, C. S. and ORTIZ DE MONTELLANO, P. R., 1991, The active sites of cytochromes P450IA1, IIB1, IIB2 and IIE1. Journal of Biological Chemistry, 266, 19258-19264.
90. SZKLARZ, G. D., HE, Y. A. and HALPERT, J. R., 1995, Site-directed mutagenesis as a tool for molecular modeling of cytochrome P4502B1. Biochemistry, 34, 14312-14322.
91. SZKLARZ, G. D., ORNSTEIN, R. L. and HALPERT, J. R., 1994, Application of 3-dimensional homology modelling of cytochrome P4502B1 for interpretation of site-directed mutagenesis results. Journal of Biomolecular Structure and Dynamics, 12, 61-78.
92. TESTA, B. and JENNER, P., 1981, Inhibitors of cytochrome P-450s and their mechanism of action. Drug Metabolism Reviews, 12, 1-117.
93. UVAROV, V. Y., SOTNICHENKO, A. I., VODOVOZOVA, E. L., MALOTKOVSKY, J. G., KOLESANOVA, E. F., LYULKIN, Y. A., STIER, A., KRUEGER, V. and ARCHAKOV, A. I., 1994, Determination of membrane-bound fragments of cytochrome P-450 2B4. European Journal of Biochemistry, 222, 483-489.
94. VON WACHENFELDT, C. and JOHNSON, E. F., 1995, Structures of eukaryotic cytochrome P450 enzymes. In Cytochrome P450, 2nd edn, edited by P. R. Ortiz de Montellano (New York: Plenum), pp. 183-223.
95. WAXMAN, D. J., 1988, Interactions of hepatic cytochromes P450 with steroid hormones. Biochemical Pharmacology, 37, 71-84.
96. WAXMAN, D. J. and AZAROFF, L., 1992, Phenobarbital induction of cytochrome P-450 gene expression. Biochemical Journal, 281, 577-592.
97. WHITE, I. N. H., DAVIES, A., SMITH, L. L., DAWSON, S. and DEMATTEIS, F., 1993, Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochemical Pharmacology, 45, 21-30.
98. 14C] tamoxifen to liver microsomes and the forms of cytochrome P450 involved. Biochemical Pharmacology, 49, 1035-1042.
99. WHITE, R. E. and MCCARTHY, M.-B., 1986, Active site mechanics of liver microsomal cytochrome P-450. Archives of Biochemistry and Biophysics, 246, 19-32.
100. WISEMAN, H. and LEWIS, D. F. V., 1996, The metabolism of tamoxifen by human cytochromes P450 is rationalized by molecular modelling of the enzyme-substrate interactions: potential importance to its proposed anticarcinogenic/carcinogenic actions. Carcinogenesis, 17, 1357-1360.
101. YU, X.-C., SHEN, S. and STROBEL, H. W., 1995, Denaturation of cytochrome P4502B1 by guanidine hydrochloride and urea: evidence for a metastable intermediate state of the active site. Biochemistry, 34, 5511-5517.
102. ZIMNIAK, P. and WAXMAN, D. J., 1993, Liver cytochrome P450 metabolism of endogenous steroid hormones, bile acids and fatty acids. In Cytochrome P450, edited by J. B. Schenkman and H. Griem (Berlin: Springer), pp. 123-144.